Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...

Authors of a recent review explored the complex relationship between CKD, COVID-19, and anemia and offered practice points based on clinical experience. Patients with chronic kidney disease (CKD) ...

Nonetheless, the number of CKD-related anemia cases continues to increase, due to population growth, aging, and other factors. Anemia cases attributable to chronic kidney disease (CKD) continue to ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

daily multivitamin does not reduce the risks of cvd in men Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Let's start with what causes anemia of ...

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States. The FDA has approved daprodustat (Jesduvroq, GSK) for the ...

TSUKUBA, JAPAN — Anemia and chronic kidney disease (CKD) are independently associated with an increased risk of new-onset atrial fibrillation (AF), and the combination of the two risk factors is ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the ...